Oxyfrin, a product by Solopharm, secured 4th place at one of the most prestigious industry awards – the professional XXVI Platinum Ounce Award – in the "Drug of the Year. Launch of the Year. Retail Segment" category.
This high achievement at the awards confirms the drug's successful market launch, its demand among consumers, and the professional recognition from experts in the pharmaceutical industry.
For many years, the Platinum Ounce has been considered one of the key awards in the Russian pharmaceutical market. It brings together leading manufacturers, pharmacy segment representatives, experts, and industry leaders, recognizing the most significant achievements and successful projects.
Oxyfrin holds a strong position in the nasal spray segment and is one of the prominent brands in the company's portfolio. The high praise from the professional community underscores the trust in the product and the quality of Solopharm's solutions.
Comment from the Solopharm Press Center:
«It is especially valuable for us when the company's products receive recognition from the professional community. Oxyfrin's fourth place in such a competitive category is the result of the team's systematic work, a deep understanding of market needs, and a constant focus on quality. We thank the award experts and everyone who trusts the Solopharm brands.»
